Amedisys (AMED) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Pay Up for Strong Management
May 3, 2017 7:30 AM EDTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $65.00.
Analyst Sheryl Skolnick is positive on management amid Q1 results. "AMED's 1Q17 result demonstrates just that: not only are cost savings real, but the balanced approach to... More
